

Press release for immediate release

## **Jarosław Oleszczuk changes his scope of involvement in Genomtec transiting from Management Board to Supervisory Board**

**Wrocław, Poland – June 23, 2021 – The company announced in the draft resolution of the Extraordinary General Meeting of Shareholders convened on July 20 this year, with the intention to appoint Dr. Jarosław Oleszczuk to the Supervisory Board of Genomtec. At the time of publication of the draft resolution announcement by Genomtec Dr. Jarosław Oleszczuk resigned from his current position of a Member of the Management Board with an effect on June 23 this year. From August 1 this year the CBO role will be assigned to by Charudutt Shah - a newly appointed Member of the Genomtec's Management Board.**

Dr. Jarosław Oleszczuk proposition to join the Supervisory Board will imply responsibilities, among others, related to creating and managing the Advisory Board, supporting the development of a commercial strategy for Genomtec ID and supporting the Management Board in acquiring strategic partners.

*- Jarek Oleszczuk made a great contribution to the development of our organization. His experience in global companies helped us to strategized globally. Our cooperation certainly does not end today. It will be continued. His responsibilities within the Supervisory Board will, in a sense, be aligned to the scope of duties conducted in the Management Board. This means that Jarek Oleszczuk will continue to participate in the Company's strategic projects, said Miron Tokarski, Co-founder & President, and significant shareholder of Genomtec.*

Dr Oleszczuk justified his decision reasoning in personal time restrictions preventing his current scope of involvement in the company's affairs.

*- I would like to thank the Company and the Management Board for our outstanding cooperation so far. During this period, we have managed to achieve many important steps in the development of the organization and its projects. Due to other professional and personal obligations, my role at Genomtec changes its character somewhat. However, as a future member of the Supervisory Board, I will continue to support the Company in all my professional capacity. I am grateful to the main Shareholders for their understanding and offer to continue my work for Genomtec as a Member of the Supervisory Board - said Dr. Jarosław Oleszczuk, former member of the Genomtec Management Board and CBO.*



The role of Chief Business Officer (CBO) will be fulfilled by Charudutt Shah, who from August 1 this year will become part of the Genomtec's Management Board.

Charudutt Shah has several years of leadership experience in the area of product commercialization, brand development and partnership with international entities. Currently, he holds the position of Marketing Director of BioMérieux SA based in Lyon, France – the world leader in laboratory diagnostics and research on infectious diseases, where he is responsible for commercial marketing in Europe, Middle East and Africa (EMEA). In his role, he oversees the launch and marketing of BioFire's syndromic infectious disease panels and instruments that rapidly identify pathogens. A major focus of his efforts are in developing go to market strategies, driving clinician awareness, market access and bringing innovative testing solutions to various healthcare ecosystems to improve patient care.

Previously, he was associated with Spartan Bioscience, based in Ottawa, Ontario, where, as Business Development Director he was responsible for sales, marketing and product distribution strategies internationally. In the years 2010 – 2014 he was a Global Marketing Manager at Luminex Corporation based in Toronto, Ontario where he managed the industry's first multiplex PCR Respiratory Viral panel including a portfolio of other infectious disease panels.

Genomtec's flagship solution – the Genomtec ID is a mobile diagnostic system employing microfluidic system and the proprietary, patented SNAAT® technology. This innovative diagnostic system will be able to carry out several tests from one sample simultaneously, including causal determination of respiratory tract infections or sexually transmitted diseases, even in 15 minutes. Genomtec ID will be used for point of care diagnostics, i.e., in doctor's offices, emergency department, and even a pharmacy.

####

**Additional information available at:**

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

**About Genomtec S.A.**

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious



diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT<sup>®</sup> isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec<sup>®</sup> SARS-CoV-2 EvaGreen<sup>®</sup> laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. The seat of Genomtec SA is located in Wroclaw in Poland and Ashford in United Kingdom.

More information: [www.genomtec.com](http://www.genomtec.com)